Advancements in Precision Medicine: TROP-2 Antigen as a Tumorigenic Driver in Breast Cancer
Released On
February 2, 2024
Expires On
February 2, 2025
Media Type
Internet
Completion Time
60 minutes
Specialty
Hematology-Oncology
Topic(s)
Breast Cancer, Oncology
This activity is provided by Med Learning Group and AMEDCO.
Nursing learners, view this Learner Notification prior to starting this activity
This activity is supported by an independent medical education grant from AstraZeneca Pharmaceuticals and Daiichi Sankyo.
Credit Available
- Physicians — maximum of 1.0 AMA PRA Category 1 Credits™
- Nurses — 1.0 Nursing Contact Hours
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
This educational activity is intended for community-based medical oncologists and other HCPs who care for patients with breast cancer.
Program Overview
This enduring HoloVision™ activity is an online program designed to advance community-based oncologists’ ability to: evaluate the biology of TROP2 in breast cancer; examine the rationale for use of TROP2-directed antibody-drug conjugates (ADCs) in breast cancer; recognize adverse effects most commonly associated with ADCs and best practices for their prevention, mitigation, and management; and formulate strategies for integrating TROP2-directed ADCs into breast cancer treatment algorithms.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Discuss the role of trophoblast cell-surface antigen 2 (TROP-2) in the proliferation, invasion, migration, and survival of cancer cells
- Review the clinical trial findings documenting the efficacy of TROP-2-targeted compounds in patients with advanced breast cancer
- Examine the adverse effects most commonly associated with antibody-drug conjugates (ADCs) and the methods of managing them in patients with advanced breast cancer
Faculty
Kevin Kalinsky, MD, MS
Professor, Department of Hematology and Medical Oncology
Emory University School of Medicine
Louisa and Rand Glenn Family Chair in Breast Cancer Research
Director, Glenn Family Breast Center
Director, Breast Medical Oncology
Winship Cancer Institute of Emory University
Atlanta, GA
Accreditation Statement
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
Credit Designation
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Med Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Amedco LLC designates this activity for a maximum of 1.0 ANCC contact hours.
Disclosure Policy Statement
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
Disclosure of Relevant Financial Relationships
- Kevin Kalinsky, MD
- Consulting Fees:: Genentech/Roche, Immunomedics, Seattle Genetics, OncoSec, 4D Pharma, Daiichi Sankyo, Puma Biotechnology, Mersana Therapeutics, Menarini Silicon Biosystems, Myovant Sciences, and Takeda.
- Ownership Interest: EQRx, Grail, Array BioPharma and Pfizer.
Method of Participation
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
Disclaimer
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
For CME questions, please contact: [email protected]
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at: https://www.medlearninggroup.com/privacy-policy/
Americans with Disabilities Act
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
Content - Copyright © 2023 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
